Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process

Li,Fang; Zhu,Tengjiao; Yue,Yao; Zhu,Xiang; Wang,Jiadong; Liang,Li

doi:10.3892/or.2018.6474

Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process

Authors:
- Fang Li
- Tengjiao Zhu
- Yao Yue
- Xiang Zhu
- Jiadong Wang
- Li Liang
View Affiliations

Affiliations: Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing 100191, P.R. China, Orthopedic Department, Peking University International Hospital, Beijing 102206, P.R. China, Department of Radiation Medicine, School of Basic Medical Science, Peking University, Beijing 100191, P.R. China, Department of Pathology, Peking University Third Hospital, Beijing 100191, P.R. China, Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing 100191, P.R. China
Published online on: June 5, 2018 https://doi.org/10.3892/or.2018.6474
Pages: 775-782

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is one of the most severe malignant tumor types worldwide. Recent studies have reported an important role of PD‑L1 in mediating immune evasion in the tumor microenvironment. In addition, increasing research has indicated that the expression of PD‑L1 is related to the epithelial‑mesenchymal transition (EMT) process, but the related mechanisms remain to be explored. In the present study, we explored the molecular mechanisms underlying the regulation of PD‑L1 expression during the EMT process in NSCLC cells treated with transforming growth factor‑β1 (TGF‑β1) and fibroblast growth factor 2 (FGF2). The phenotypic alteration associated with EMT was evaluated by western blotting and confirmed by a wound‑healing assay. The results revealed that EMT markedly promoted the expression of PD‑L1 in the A549 cell line, while having no obvious influence on the H1650 and H1975 cells. Furthermore, the AKT pathway inhibitor LY294002, the ERK pathway inhibitor PD98059 and the TAK1 pathway inhibitor 5Z‑7 inhibited the expression of PD‑L1 in A549 and H1650 cells, but not in H1975 cells, during the EMT process. Moreover, our study indicated that the AKT, ERK and TAK1 pathways regulated the expression of PD‑L1 by mediating transportation of the transcription factor Stat3 and the p65 subunit of NF‑κB from the cytoplasm to the nucleus, with such findings determined by western blotting and flow cytometric analyses. Furthermore, the expression of PD‑L1 was significantly increased following treatment with gefitinib in a tumor xenograft model. In summary, our results support the role of ERK, AKT and TAK1 in mediating the expression of PD‑L1 during the EMT process, and indicate a promising strategy of PD‑L1‑targeted therapy for the clinical treatment of NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
3	Shi L, Tang J, Tong L and Liu Z: Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. Lung Cancer. 83:231–239. 2014. View Article : Google Scholar : PubMed/NCBI
4	Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B and Zhou C: Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci. 56:275–284. 2011. View Article : Google Scholar : PubMed/NCBI
5	Rolff J, Becker M, Merk J, Hoffmann J and Fichtner I: Preclinical study of a combination of erlotinib and bevacizumab in early stages of unselected non-small cell lung cancer patient-derived xenografts. Target Oncol. 11:507–514. 2016. View Article : Google Scholar : PubMed/NCBI
6	Lin L and Bivona TG: Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract. 2012:8172972012.PubMed/NCBI
7	Sato M, Shames DS and Hasegawa Y: Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology. 17:1048–1059. 2012. View Article : Google Scholar : PubMed/NCBI
8	Voena C, Varesio LM, Zhang L, Menotti M, Poggio T, Panizza E, Wang Q, Minero VG, Fagoonee S, Compagno M, et al: Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. Oncotarget. 7:33316–33330. 2016. View Article : Google Scholar : PubMed/NCBI
9	Wu F, Li J, Jang C, Wang J and Xiong J: The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma. Int J Clin Exp Pathol. 7:6653–6661. 2014.PubMed/NCBI
10	Jiao D, Wang J, Lu W, Tang X, Chen J, Mou H and Chen QY: Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer. Mol Ther Oncolytics. 3:160182016. View Article : Google Scholar : PubMed/NCBI
11	Liu ZC, Chen XH, Song HX, Wang HS, Zhang G, Wang H, Chen DY, Fang R, Liu H, Cai SH and Du J: Snail regulated by PKC/GSK-3β pathway is crucial for EGF-induced epithelial-mesenchymal transition (EMT) of cancer cells. Cell Tissue Res. 358:491–502. 2014. View Article : Google Scholar : PubMed/NCBI
12	Bi WR, Yang CQ and Shi Q: Transforming growth factor-β1 induced epithelial-mesenchymal transition in hepatic fibrosis. Hepatogastroenterology. 59:1960–1963. 2012.PubMed/NCBI
13	Kaminska B, Wesolowska A and Danilkiewicz M: TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol. 52:329–337. 2005.PubMed/NCBI
14	Shintani Y, Okimura A, Sato K, Nakagiri T, Kadota Y, Inoue M, Sawabata N, Minami M, Ikeda N, Kawahara K, et al: Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg. 92:1794–1804; discussion 1804. 2011. View Article : Google Scholar : PubMed/NCBI
15	Chen XF, Zhang HJ, Wang HB, Zhu J, Zhou WY, Zhang H, Zhao MC, Su JM, Gao W, Zhang L, et al: Transforming growth factor-β1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep. 39:3549–3556. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhang HJ, Wang HY, Zhang HT, Su JM, Zhu J, Wang HB, Zhou WY, Zhang H, Zhao MC, Zhang L and Chen XF: Transforming growth factor-β1 promotes lung adenocarcinoma invasion and metastasis by epithelial-to-mesenchymal transition. Mol Cell Biochem. 355:309–314. 2011. View Article : Google Scholar : PubMed/NCBI
17	Cervantes-Arias A, Pang LY and Argyle DJ: Epithelial-mesenchymal transition as a fundamental mechanism underlying the cancer phenotype. Vet Comp Oncol. 11:169–184. 2013. View Article : Google Scholar : PubMed/NCBI
18	Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
19	Dai S, Jia R, Zhang X, Fang Q and Huang L: The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol. 290:72–79. 2014. View Article : Google Scholar : PubMed/NCBI
20	Bachy E and Coiffier B: Anti-PD1 antibody: A new approach to treatment of lymphomas. Lancet Oncol. 15:7–8. 2014. View Article : Google Scholar : PubMed/NCBI
21	Gunturi A and McDermott DF: Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol. 15:137–146. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kudo-Saito C, Shirako H, Takeuchi T and Kawakami Y: Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
23	Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, Sun X, Li GG, Hu QD, Fu QH and Liang TB: Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 76:818–830. 2016. View Article : Google Scholar : PubMed/NCBI
24	Li F, Zhu T, Cao B, Wang J and Liang L: Apatinib enchance antitumor activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer. 84:184–192. 2017. View Article : Google Scholar : PubMed/NCBI
25	Hellmann M, Rizvi N, Wolchok JD and Chan TA: Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Mol Cell Oncol. 3:e10489292015. View Article : Google Scholar : PubMed/NCBI
26	Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J and Hemminki K: Metastatic sites and survival in lung cancer. Lung Cancer. 86:78–84. 2014. View Article : Google Scholar : PubMed/NCBI
27	Singh D, Attri BK, Gill RK and Bariwal J: Review on EGFR Inhibitors: Critical updates. Mini Rev Med Chem. 16:1134–1166. 2016. View Article : Google Scholar : PubMed/NCBI
28	Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N and Takahashi K: Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Respir Investig. 52:82–91. 2014. View Article : Google Scholar : PubMed/NCBI
29	Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44:852–860. 2012. View Article : Google Scholar : PubMed/NCBI
30	Nurwidya F, Takahashi F, Murakami A and Takahashi K: Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat. 44:151–156. 2012. View Article : Google Scholar : PubMed/NCBI
31	Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 3:75ra26. 2011. View Article : Google Scholar : PubMed/NCBI
32	Saijo N: Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat. 44:1–10. 2012. View Article : Google Scholar : PubMed/NCBI
33	Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R: Epithelial-to-mesemchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature. 527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
34	Diepenbruck M and Christofori G: Epithelial to mesemchymal transition (EMT) and metastais: Yes, no, maybe? Curr Opin Cell Biol. 43:7–13. 2016. View Article : Google Scholar : PubMed/NCBI
35	Strippoli R, Benedicto I, Perez Lozano ML, Pellinen T, Sandoval P, Lopez-Cabrera M and del Pozo MA: Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells. PLoS One. 7:e314922012. View Article : Google Scholar : PubMed/NCBI
36	Liu W, Kovacevic Z, Peng Z, Jin R, Wang P, Yue F, Zheng M, Huang ML, Jansson PJ, Richardson V, et al: The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: New therapeutic targets. Oncotarget. 6:35522–35541. 2015.PubMed/NCBI
37	Sequist LV, Bell DW, Lynch TJ and Haber DA: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 25:587–595. 2007. View Article : Google Scholar : PubMed/NCBI
38	Said NA and Williams ED: Growth factors in induction of epithelial-mesenchymal transition and metastasis. Cells Tissues Organs. 193:85–97. 2011. View Article : Google Scholar : PubMed/NCBI